{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:47:33Z","timestamp":1791920853964,"version":"4.3.4"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.cbi.2021.109652","type":"journal-article","created":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T01:43:43Z","timestamp":1631324623000},"page":"109652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1\/miR-454\u20133p\/ZEB1 axis-mediated VEGFA expression and PD-1\/PD-L1 checkpoint in NSCLC"],"prefix":"10.1016","volume":"349","author":[{"given":"Yang","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Yang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao-Hua","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-3135","authenticated-orcid":false,"given":"Yong-Biao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2021.109652_bib1","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.cbi.2021.109652_bib2","doi-asserted-by":"crossref","first-page":"15009","DOI":"10.1038\/nrdp.2015.9","article-title":"Non-small-cell lung cancer","volume":"1","author":"Gridelli","year":"2015","journal-title":"Nature reviews. Disease primers"},{"key":"10.1016\/j.cbi.2021.109652_bib3","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: current treatment and future advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.cbi.2021.109652_bib4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3892\/mco.2014.410","article-title":"Specific organ metastases and survival in metastatic non-small-cell lung cancer","volume":"3","author":"Tamura","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.cbi.2021.109652_bib5","first-page":"XE01","article-title":"Tumour angiogenesis and angiogenic inhibitors: a review","volume":"9","author":"Yadav","year":"2015","journal-title":"J. Clin. Diagn. Res."},{"key":"10.1016\/j.cbi.2021.109652_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18102021","article-title":"Angiogenesis inhibitors in NSCLC","volume":"18","author":"Manzo","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cbi.2021.109652_bib7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/bdrc.21096","article-title":"Thalidomide-induced teratogenesis: history and mechanisms","volume":"105","author":"Vargesson","year":"2015","journal-title":"Birth Defects Res C Embryo Today"},{"key":"10.1016\/j.cbi.2021.109652_bib8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00001622-200211000-00008","article-title":"Thalidomide and immunomodulatory drugs as cancer therapy","volume":"14","author":"Raje","year":"2002","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.cbi.2021.109652_bib9","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cbi.2021.109652_bib10","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.biocel.2007.01.022","article-title":"The thalidomide saga","volume":"39","author":"Melchert","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.cbi.2021.109652_bib11","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.4103\/0366-6999.169068","article-title":"Thalidomide effects in patients with hereditary hemorrhagic telangiectasia during therapeutic treatment and in fli-EGFP transgenic Zebrafish model","volume":"128","author":"Peng","year":"2015","journal-title":"Chinese Med J"},{"key":"10.1016\/j.cbi.2021.109652_bib12","first-page":"2583","article-title":"Thalidomide combined with chemotherapy in treating patients with advanced lung cancer","volume":"17","author":"Li","year":"2016","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.cbi.2021.109652_bib13","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/carcin\/bgh210","article-title":"The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARgamma pathway","volume":"25","author":"DeCicco","year":"2004","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cbi.2021.109652_bib14","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1053\/j.seminoncol.2015.05.003","article-title":"Cancer and the immune system: Basic concepts and targets for intervention","volume":"42","author":"Pardoll","year":"2015","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.cbi.2021.109652_bib15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cbi.2021.109652_bib16","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cbi.2021.109652_bib17","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.cbi.2021.109652_bib18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune escape mechanisms as a guide for cancer immunotherapy, Clinical cancer research : an","volume":"21","author":"Beatty","year":"2015","journal-title":"official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.cbi.2021.109652_bib19","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.4161\/onci.21335","article-title":"Targeting PD-1\/PD-L1 interactions for cancer immunotherapy","volume":"1","author":"Zitvogel","year":"2012","journal-title":"OncoImmunology"},{"key":"10.1016\/j.cbi.2021.109652_bib20","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cbi.2021.109652_bib21","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.cbi.2021.109652_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12943-019-1073-4","article-title":"EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression","volume":"18","author":"Peng","year":"2019","journal-title":"Mol. Canc."},{"key":"10.1016\/j.cbi.2021.109652_bib23","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","article-title":"Immunotherapy in non-small cell lung cancer: facts and hopes, clinical cancer research","volume":"25","author":"Doroshow","year":"2019","journal-title":"official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.cbi.2021.109652_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12457","article-title":"Long non-coding RNAs in melanoma","volume":"51","author":"Yu","year":"2018","journal-title":"Cell Prolif"},{"key":"10.1016\/j.cbi.2021.109652_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-016-0530-6","article-title":"Long noncoding RNAs in cancer: mechanisms of action and technological advancements","volume":"15","author":"Bartonicek","year":"2016","journal-title":"Mol. Canc."},{"key":"10.1016\/j.cbi.2021.109652_bib26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.molmed.2018.01.001","article-title":"Therapeutic targeting of long non-coding RNAs in cancer","volume":"24","author":"Arun","year":"2018","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.cbi.2021.109652_bib27","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20193309","article-title":"Long non-coding RNA FGD5-AS1 promotes non-small cell lung cancer cell proliferation through sponging hsa-miR-107 to up-regulate FGFRL1","volume":"40","author":"Fan","year":"2020","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.cbi.2021.109652_bib28","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2174\/138920210793175895","article-title":"MicroRNA: Biogenesis, function and role in cancer","volume":"11","author":"Macfarlane","year":"2010","journal-title":"Curr. Genom."},{"key":"10.1016\/j.cbi.2021.109652_bib29","doi-asserted-by":"crossref","first-page":"35714","DOI":"10.1038\/srep35714","article-title":"MicroRNA-574-5p promotes metastasis of non-small cell lung cancer by targeting PTPRU","volume":"6","author":"Zhou","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cbi.2021.109652_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-020-00848-8","article-title":"The role of cancer-derived microRNAs in cancer immune escape","volume":"13","author":"Yi","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cbi.2021.109652_bib31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.biopha.2016.03.029","article-title":"MiR-454 promotes the progression of human non-small cell lung cancer and directly targets PTEN","volume":"81","author":"Zhu","year":"2016","journal-title":"Biomedic. Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"key":"10.1016\/j.cbi.2021.109652_bib32","first-page":"119","article-title":"Downregulation of calbindin 1 by miR-454-3p suppresses cell proliferation in nonsmall cell lung cancer in vitro","volume":"34","author":"Jin","year":"2019","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.cbi.2021.109652_bib33","first-page":"1665","article-title":"Aquaporin 5 promotes tumor migration and angiogenesis in non-small cell lung cancer cell line H1299","volume":"19","author":"Elkhider","year":"2020","journal-title":"Oncology letters"},{"key":"10.1016\/j.cbi.2021.109652_bib34","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41419-019-1886-5","article-title":"LncRNA SNHG14\/miR-5590-3p\/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1\/PD-L1 checkpoint","volume":"10","author":"Zhao","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cbi.2021.109652_bib35","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.prp.2019.01.013","article-title":"Effects of mesenchymal stem cells harboring the Interferon-beta gene on A549 lung cancer in nude mice","volume":"215","author":"Chen","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.cbi.2021.109652_bib36","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1038\/s41388-018-0298-9","article-title":"C5a induces A549 cell proliferation of non-small cell lung cancer via GDF15 gene activation mediated by GCN5-dependent KLF5 acetylation","volume":"37","author":"Zhao","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.cbi.2021.109652_bib37","doi-asserted-by":"crossref","first-page":"6924","DOI":"10.3748\/wjg.v21.i22.6924","article-title":"Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors","volume":"21","author":"Basilio-de-Oliveira","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cbi.2021.109652_bib38","doi-asserted-by":"crossref","first-page":"eaar2766","DOI":"10.1126\/sciadv.aar2766","article-title":"Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles","volume":"4","author":"Ricklefs","year":"2018","journal-title":"Sci Adv"},{"key":"10.1016\/j.cbi.2021.109652_bib39","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nrc.2017.118","article-title":"EMT in cancer","volume":"18","author":"Brabletz","year":"2018","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.cbi.2021.109652_bib40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13046-019-1156-5","article-title":"ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa\/VEGFR2\/ERK pathway","volume":"38","author":"Zhang","year":"2019","journal-title":"J. Exp. Clin. Canc. Res. : CR (Clim. Res.)"},{"key":"10.1016\/j.cbi.2021.109652_bib41","article-title":"ZEB1 upregulates VEGF expression and stimulates angiogenesis in breast cancer","volume":"11","author":"Liu","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.cbi.2021.109652_bib42","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.cbi.2021.109652_bib43","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1158\/1078-0432.CCR-19-0994","article-title":"Crizotinib in MET-deregulated or ROS1-rearranged pretreated non-small cell lung cancer (METROS): A phase II, prospective, Multicenter, two-Arms trial","volume":"25","author":"Landi","year":"2019","journal-title":"Clin. Canc. Res. :Official J. Am. Assoc. Canc. Res."},{"key":"10.1016\/j.cbi.2021.109652_bib44","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature09870","article-title":"FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR","volume":"471","author":"Bivona","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.cbi.2021.109652_bib45","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3892\/ol.2016.4904","article-title":"miR-429 promotes the proliferation of non-small cell lung cancer cells via targeting DLC-1","volume":"12","author":"Xiao","year":"2016","journal-title":"Oncology letters"},{"key":"10.1016\/j.cbi.2021.109652_bib46","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.1200\/JCO.2009.21.9733","article-title":"Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer","volume":"27","author":"Lee","year":"2009","journal-title":"J. Clin. Oncol.: Official J. Am. Soc. Clinic. Oncol."},{"key":"10.1016\/j.cbi.2021.109652_bib47","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.lungcan.2007.08.032","article-title":"Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer","volume":"59","author":"Lee","year":"2008","journal-title":"Lung Canc."},{"key":"10.1016\/j.cbi.2021.109652_bib48","first-page":"48","article-title":"Pilot and safety trial of carboplatin, paclitaxel, and thalidomide in advanced non small-cell lung cancer","volume":"2","author":"Merchant","year":"2000","journal-title":"Clin. Lung Canc."},{"key":"10.1016\/j.cbi.2021.109652_bib49","first-page":"3193","article-title":"Synergistic inhibition of thalidomide and icotinib on human non-small cell lung carcinomas through ERK and AKT signaling","volume":"24","author":"Sun","year":"2018","journal-title":"Med. Sci. Mon. Int. Med. J. Exp. Clin. Res. : international medical journal of experimental and clinical research"},{"key":"10.1016\/j.cbi.2021.109652_bib50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.prp.2017.10.016","article-title":"Use of erlotinib and thalidomide in advanced NSCLC patients with acquired resistance to erlotinib: a pilot study","volume":"214","author":"Wang","year":"2018","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.cbi.2021.109652_bib51","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3892\/ol.2016.4580","article-title":"Long non-coding RNA CCAT2 functions as an oncogene in hepatocellular carcinoma, regulating cellular proliferation, migration and apoptosis","volume":"12","author":"Zhou","year":"2016","journal-title":"Oncology letters"},{"key":"10.1016\/j.cbi.2021.109652_bib52","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3892\/etm.2013.933","article-title":"A long non-coding RNA, PTCSC3, as a tumor suppressor and a target of miRNAs in thyroid cancer cells","volume":"5","author":"Fan","year":"2013","journal-title":"Experimental and therapeutic medicine"},{"key":"10.1016\/j.cbi.2021.109652_bib53","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ccr.2014.03.010","article-title":"A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma","volume":"25","author":"Yuan","year":"2014","journal-title":"Canc. Cell"},{"key":"10.1016\/j.cbi.2021.109652_bib54","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/0008-5472.CAN-12-2850","article-title":"The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells","volume":"73","author":"Gutschner","year":"2013","journal-title":"Canc. Res."},{"key":"10.1016\/j.cbi.2021.109652_bib55","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1101\/gad.270959.115","article-title":"Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss","volume":"30","author":"Arun","year":"2016","journal-title":"Genes Dev."},{"key":"10.1016\/j.cbi.2021.109652_bib56","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/jim-2019-001080","article-title":"lncRNA SLC16A1-AS1 as a novel prognostic biomarker in non-small cell lung cancer","volume":"68","author":"Liu","year":"2020","journal-title":"J. Invest. Med."},{"key":"10.1016\/j.cbi.2021.109652_bib57","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pharmthera.2016.03.004","article-title":"Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma","volume":"161","author":"Parasramka","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cbi.2021.109652_bib58","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1158\/1535-7163.MCT-18-0725","article-title":"miR-454-3p is an exosomal biomarker and functions as a tumor suppressor in glioma","volume":"18","author":"Shao","year":"2019","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.cbi.2021.109652_bib59","first-page":"2795","article-title":"High miR-454-3p expression predicts poor prognosis in hepatocellular carcinoma","volume":"11","author":"Li","year":"2019","journal-title":"Canc. Manag. Res."},{"key":"10.1016\/j.cbi.2021.109652_bib60","doi-asserted-by":"crossref","first-page":"9067","DOI":"10.3892\/mmr.2017.7758","article-title":"MicroRNA-454 inhibits tumor cell proliferation, migration and invasion by downregulating zinc finger Eboxbinding homeobox 1 in gastric cancer","volume":"16","author":"Song","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.cbi.2021.109652_bib61","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1172\/JCI76725","article-title":"ZEB1 drives epithelial-to-mesenchymal transition in lung cancer","volume":"126","author":"Larsen","year":"2016","journal-title":"JCI (J. Clin. Investig.)"},{"key":"10.1016\/j.cbi.2021.109652_bib62","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/cas.13237","article-title":"Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma","volume":"108","author":"Tsutsumi","year":"2017","journal-title":"Canc. Sci."},{"key":"10.1016\/j.cbi.2021.109652_bib63","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1172\/JCI131507","article-title":"Inactivation of endothelial ZEB1 impedes tumor progression and sensitizes tumors to conventional therapies","volume":"130","author":"Fu","year":"2020","journal-title":"JCI (J. Clin. Investig.)"}],"updated-by":[{"DOI":"10.1016\/j.cbi.2022.110083","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000}}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279721002908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279721002908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:05:08Z","timestamp":1757858708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279721002908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":63,"alternative-id":["S0009279721002908"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2021.109652","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.cbi.2022.110083","asserted-by":"object"}]},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1\/miR-454\u20133p\/ZEB1 axis-mediated VEGFA expression and PD-1\/PD-L1 checkpoint in NSCLC","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2021.109652","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109652"}}